Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)
This study is not yet open for participant recruitment.
Verified by Nitric BioTherapeutics, Inc, December 2008
Sponsored by: Nitric BioTherapeutics, Inc
Information provided by: Nitric BioTherapeutics, Inc
ClinicalTrials.gov Identifier: NCT00790608
  Purpose

The purpose of the study is to determine if topically applied nitric oxide gas is effective in reducing the quantity of bacteria (including MRSA)in a wound.


Condition Intervention Phase
Skin Ulcers
Methicillin-Resistant Staphylococcus Aureus Infection
Drug: Nitric Oxide
Phase II

Drug Information available for: Nitric oxide Methicillin Methicillin sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase II Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers

Further study details as provided by Nitric BioTherapeutics, Inc:

Primary Outcome Measures:
  • Change in bioburden (specifically MRSA)as assessed via quantitative cultures. [ Time Frame: 10 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement in the condition of the ulcer as judged by comparative photography and independent clinical assessment [ Time Frame: 10 Days ] [ Designated as safety issue: No ]
  • Incidence of adverse events [ Time Frame: 10 Days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: January 2009
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Nitric Oxide
    Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have given written informed consent
  • Must be ≥ 18 years of age and not of child bearing potential
  • Must have an ulcer in which the presence of MRSA has been identified, but which is not clinically infected
  • Must have an ulcer size not to extend beyond the inner borders of the dressing

Exclusion Criteria:

  • Is a female of child bearing years or who could become pregnant
  • Is < 18 years of age
  • Has an clinically infected skin ulcer
  • Has a ulcer that is being treated with a topical antimicrobial agent or has been treated with a topical antimicrobial agent during 3 days prior to enrolment
  • Has been using systemic antibiotics during 7 days prior to enrolment into this study
  • Has an ulcer which is identified as malignant in origin (e.g. Marjolin's ulcer)
  • Has an ulcer size beyond the inner borders of the dressing
  • Is septic or has other signs of an invasive infection
  • Has used any investigational drug within 30 days preceding study participation.
  • Suffers from a condition, which, in the opinion of the Investigator, would compromise his or her safety.
  • Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.
  • Has a known allergy to any of the products that are part of this protocol
  • Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.
  • Is using any of the prohibited concomitant medications or treatments
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00790608

Contacts
Contact: Nicola Ivins + 44 (0) 2920746319 ivinsnm@Cardiff.ac.uk

Locations
United Kingdom
Department of Wound Healing, Cardiff University
Cardiff, United Kingdom, CF14 4XN
Sponsors and Collaborators
Nitric BioTherapeutics, Inc
Investigators
Principal Investigator: Keith Harding, MB ChB, MRGCP, FRCS Department of Wound Healing, Cardiff University
  More Information

Responsible Party: Nitric BioTherapeutics ( Tanya Rhodes/Chief Technology Officer )
Study ID Numbers: CTP 5, EudraCT 2008-001287-36
Study First Received: November 12, 2008
Last Updated: December 29, 2008
ClinicalTrials.gov Identifier: NCT00790608  
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study placed in the following topic categories:
Nitric Oxide
Bacterial Infections
Staphylococcal Infections
Gram-Positive Bacterial Infections
Methicillin
Skin Diseases
Ulcer
Skin Ulcer

Additional relevant MeSH terms:
Anti-Infective Agents
Respiratory System Agents
Vasodilator Agents
Neurotransmitter Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Asthmatic Agents
Cardiovascular Agents
Infection
Protective Agents
Pharmacologic Actions
Anti-Bacterial Agents
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Free Radical Scavengers
Endothelium-Dependent Relaxing Factors
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on January 16, 2009